Elaine Del nery  
**Platform Supervisor**  
bfx-screening@curie.fr

Franck Perez  
**Scientific Director**  
franck.perez@curie.fr  
Tel: +33 1 56 24 63 88

Jacques Camonis  
**Directeur de recherche émérite**  
jacques.camonis@curie.fr  
Tel: +33 1 56 24 66 54

Philippe Benaroch  
**Scientific Director**  
philippe.benaroch@curie.fr  
Tel: +33 1 56 24 64 32
BioPhenics facility specializes in chemical biology as it relates drug discovery, biological probe discovery and phenotypic characterization of small-molecule effects (siRNAs and chemical compounds) on cellular systems. The facility provides basic and applied research teams with the technical resources and expertise needed to carry out high-content screens.

The facility has enabled screening projects for different research groups in Europe, most of them located in cancer centers, aiming to benefit from the platform capabilities for identifying both the genes and pathways that mediate disease states and novel compounds that modulate these pathways. BioPhenics operates with a philosophy of collaboration, rather than fee-for-service. These screens can be carried out using small molecule or siRNA libraries curated by BioPhenics or with custom libraries developed by researchers.

**Objectifs**

- Development of cell-based assays for large-scale identification of protein markers of a physiological or functional status of therapeutic response.
- Analysis of phenotypic profiles of genes and chemical libraries based on their diagnostic / therapeutic interest.
- Identification of bio-active molecules, even though they do not present an immediately exploitable therapeutic effect (molecular tools)
- Early drug discovery process from target identification to lead molecule characterization

BioPhenics is designed to function both as an intellectual base and a core research facility for researchers in their goal to develop novel treatments for diseases. BioPhenics Scientific Staff provides the intellectual capital, collaborative opportunities and access to state-of-the-art technologies in chemical biology and participates in the training of future research scientists and health care practitioners.

**Equipements**

The robotic platform is a flexible, modular, specialized system for the full automation of a wide variety of 96 and 384-well cell-based and biochemical assays. In addition to housing the instrumentation and robotics required for traditional high-throughput liquid handling (TECAN EVO, MAP TiterTek, Thermo Scientific Multidrop), the facility houses two cutting-edge High Content Image-based instruments (INCell 2000 and INCell 2200 systems) for small-molecule discovery research and analysis in fixed cells. The cell culturing laboratory ensures the
continuous provision of cell culture samples for automated testing. They are located in a positive-pressure room fully equipped for preparation and maintenance of cell cultures in a safe and sterile environment. Standard operating procedures are implemented to ensure the continuous production of consistent high-quality cell-based assays.

Contact

bfx-screening@curie.fr

More information on the **Biophenics website**

Key publications

**Year of publication 2015**

Priscille Brodin, Elaine DelNery, Emmanuelle Soleilhac (2015 Mar 4)

[High content screening in chemical biology: overview and main challenges].
*Médecine sciences* : M/S : 187-96 : [DOI : 10.1051/medsci/20153102016](https://doi.org/10.1051/medsci/20153102016)

**Year of publication 2013**


A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation.

Julien Ablain, Magdalena Leiva, Laurent Peres, Julien Fonsart, Elodie Anthony, Hugues de Thé (2013 Mar 18)

Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.